Cantor Fitzgerald Weighs in on Organogenesis Holdings Inc.’s FY2024 Earnings (NASDAQ:ORGO)

Organogenesis Holdings Inc. (NASDAQ:ORGOFree Report) – Analysts at Cantor Fitzgerald increased their FY2024 earnings estimates for Organogenesis in a research note issued on Wednesday, October 9th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings per share of ($0.17) for the year, up from their prior forecast of ($0.20). The consensus estimate for Organogenesis’ current full-year earnings is ($0.19) per share.

Separately, Lake Street Capital initiated coverage on shares of Organogenesis in a research report on Friday, June 28th. They set a “buy” rating and a $5.00 price target on the stock.

View Our Latest Analysis on Organogenesis

Organogenesis Price Performance

NASDAQ:ORGO opened at $3.07 on Friday. Organogenesis has a 52 week low of $1.96 and a 52 week high of $4.70. The firm has a market cap of $406.99 million, a price-to-earnings ratio of -23.69 and a beta of 1.60. The firm’s 50-day simple moving average is $2.76 and its 200 day simple moving average is $2.75. The company has a debt-to-equity ratio of 0.22, a quick ratio of 2.42 and a current ratio of 2.73.

Organogenesis (NASDAQ:ORGOGet Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.11). The company had revenue of $130.23 million during the quarter, compared to the consensus estimate of $122.48 million. Organogenesis had a negative net margin of 3.69% and a negative return on equity of 6.03%.

Institutional Investors Weigh In On Organogenesis

Large investors have recently bought and sold shares of the company. Assenagon Asset Management S.A. boosted its stake in shares of Organogenesis by 309.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 3,977,124 shares of the company’s stock valued at $11,136,000 after purchasing an additional 3,005,450 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Organogenesis by 76.9% in the 2nd quarter. AQR Capital Management LLC now owns 2,268,760 shares of the company’s stock valued at $6,353,000 after purchasing an additional 986,132 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Organogenesis in the 1st quarter valued at approximately $1,846,000. Acadian Asset Management LLC boosted its stake in shares of Organogenesis by 18.6% in the 1st quarter. Acadian Asset Management LLC now owns 3,001,679 shares of the company’s stock valued at $8,521,000 after purchasing an additional 471,741 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Organogenesis by 19.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,036,743 shares of the company’s stock valued at $5,702,000 after purchasing an additional 333,123 shares in the last quarter. 49.57% of the stock is currently owned by institutional investors and hedge funds.

Organogenesis Company Profile

(Get Free Report)

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.

Further Reading

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.